Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Non-Small Cell Lung Cancer Metastatic 1Metastatic Non-small Cell Lung Cancers 1Lung Neoplasms 1Lazertinib 1Advanced Solid Tumors 1

Interventions

Paclitaxel 2Injections 2toripalimab 1tislelizumab 1surufatinib 1sotorasib 1osimertinib 1netrin-1 inhibitor NP137 1lazertinib 1fluzoparib 1camrelizumab 1Panitumumab 1PM 01183 1Nivolumab 1Ipilimumab 1HMPL-013 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 1Bevacizumab 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Solid Tumors × lazertinib × Clear all
NCT05541822 2025-05-22

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Abion Inc

Phase 2 Recruiting
178 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡